BridgeBio Pharma Total Non-Operating Income/Expense 2018-2024 | BBIO

  • BridgeBio Pharma annual total non-operating income/expense for 2024 was $0.051B, a 210.68% decline from 2023.
  • BridgeBio Pharma annual total non-operating income/expense for 2023 was $-0.046B, a 266.54% decline from 2022.
  • BridgeBio Pharma annual total non-operating income/expense for 2022 was $0.028B, a 380.49% decline from 2021.

Historical Chart (TTM)

Click on chart icon to view chart
Click on table icon to view table

Quarterly

Click on chart icon to view chart
Click on table icon to view table

Quarterly - YOY Change

Click on chart icon to view chart
Click on table icon to view table

Annual

Click on chart icon to view chart
Click on table icon to view table

Annual % Change

Click on chart icon to view chart
Click on table icon to view table
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$19.4B
Dr Reddy's Laboratories (RDY)$11.2B
Bausch Health Cos (BHC)$2.4B
Supernus Pharmaceuticals (SUPN)$1.9B
Amphastar Pharmaceuticals (AMPH)$1.5B
Personalis (PSNL)$412M
Taysha Gene Therapies (TSHA)$336M
Assembly Biosciences (ASMB)$81M
Sol-Gel Technologies (SLGL)$16M
Evoke Pharma (EVOK)$8M
Teligent (TLGT)$0M